Inhibiting histone deacetylase 1 suppresses both inflammation and bone loss in arthritis

Cantley, Melissa D., Fairlie, David P., Bartold, P. Mark, Marino, Victor, Gupta, Praveer K. and Haynes, David R. (2015) Inhibiting histone deacetylase 1 suppresses both inflammation and bone loss in arthritis. Rheumatology, 54 9: 1713-1723. doi:10.1093/rheumatology/kev022

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads

Author Cantley, Melissa D.
Fairlie, David P.
Bartold, P. Mark
Marino, Victor
Gupta, Praveer K.
Haynes, David R.
Title Inhibiting histone deacetylase 1 suppresses both inflammation and bone loss in arthritis
Journal name Rheumatology   Check publisher's open access policy
ISSN 1462-0324
Publication date 2015-03-31
Sub-type Article (original research)
DOI 10.1093/rheumatology/kev022
Open Access Status
Volume 54
Issue 9
Start page 1713
End page 1723
Total pages 11
Place of publication Oxford, United Kingdom
Publisher Oxford University Press
Collection year 2016
Language eng
Formatted abstract
Objective. Histone deacetylase 1 (HDAC1) is highly expressed in the synovium of RA patients. Thus we aimed to investigate a novel HDAC inhibitor (HDACi), NW-21, designed to target HDAC1. The effect of NW-21 on osteoclast formation and activity, cytokine and chemokine expression in vitro and arthritis in mice was assessed.

Methods. The effects on human osteoclast formation and activity derived from human blood monocytes stimulated with receptor activator of nuclear factor κB ligand (RANKL) and M-CSF were assessed. The anti-inflammatory activity of NW-21 was assessed using human monocytes stimulated with either TNF-α or lipopolysaccharide for 24 h. mRNA expression of monocyte chemotactic protein 1 (MCP-1), TNF-α, macrophage inflammatory protein 1α (MIP-1α), IL-1 and RANTES (regulated on activation, normal T cell expressed and secreted) was assessed. The effect of NW-21 in the collagen antibody–induced arthritis model was assessed following daily oral administration at 5 mg/kg/day. The HDAC1 inhibitors NW-21 and MS-275 were compared with a broad-acting HDACi, 1179.4b. Effects on inflammation and bone were assessed using paw inflammation scoring, histology and live animal micro-CT.

Results. NW-21 suppressed osteoclast formation and activity as well as significantly reducing mRNA expression of MCP-1 and MIP-1α in monocytes stimulated by lipopolysaccharide or TNF-α (P < 0.05) in vitro. Only inhibitors that targeted HDAC1 (NW-21 and MS-275) reduced inflammation and bone loss in the arthritis model.

Conclusion. The results indicate that inhibitors targeting HDAC1, such as NW-21 and MS-275, may be useful for treating RA, as such drugs can simultaneously target both inflammation and bone resorption.
Keyword Histone deacetylase 1
Bone loss
Collagen antibody–induced arthritis
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ
Additional Notes Advance Access published March 31, 2015

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2016 Collection
Institute for Molecular Bioscience - Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 6 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 4 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 14 Apr 2015, 09:54:02 EST by Susan Allen on behalf of Institute for Molecular Bioscience